ABCR  Vol.5 No.2 , April 2016
The Prognostic Significance of the Preoperative Platelet-Lymphocyte Ratio in Japanese Patients with Localized Breast Cancer
Abstract: Inflammation has been shown to be a factor in tumorigenesis. The circulating platelet to lymphocyte ratio (PLR) is a representative index of systemic inflammation. In this study, we analyzed the association between preoperative PLR levels and clinicopathological variables in two hundred sixty-four Japanese patients with localized breast carcinoma. We also evaluated the prognostic significance of preoperative PLR levels using the Cox proportional hazard model. Seventy-five patients (28.4%) had elevated PLR values, whereas 189 (71.6%) had depressed PLR values. The PLR correlated significantly with venous invasion (P < 0.05). Disease-free survival rates were significantly worse among patients with elevated PLR values than among those with lower PLR value (5-year survival, 81.6% vs. 90.7%, respectively; P < 0.05). In multivariate analysis, elevated PLR, nuclear grade, and lymph node involvement were significant prognostic factors for disease-free survival in patients with breast carcinoma (P < 0.05). Preoperative PLR levels may be an independent prognostic factor in patients with breast carcinoma.
Cite this paper: Takeuchi, H. , Fukuyama, S. , Kubo, N. , Hiroshige, S. , Kawanaka, H. , Yoshikawa, Y. , Yano, T. (2016) The Prognostic Significance of the Preoperative Platelet-Lymphocyte Ratio in Japanese Patients with Localized Breast Cancer. Advances in Breast Cancer Research, 5, 49-57. doi: 10.4236/abcr.2016.52005.

[1]   Hortobagyi, G.N., de la Garza Salazar, J., Pritchard, K., Amadori, D., Haidinger, R., Hudis, C.A., Khaled, H., Liu, M.C., Martin, M., Namer, M., O’Shaughnessy, J.A., Shen, Z.Z. and Albain, K.S. (2005) The Global Breast Cancer Buden: Variation in Epidemiology and Survival. Clinical Breast Cancer, 6, 391-401.

[2]   Qiu, D.M., Katanoda, K., Marugame, T. and Sobue, T. (2009) A Joinpoint Regression Analysis of Long-Term Trends in Cancer Mortality in Japan (1958-2004). International Journal of Cancer, 124, 443-448.

[3]   Kraeima, J., Siesling, S., Vliegen, I.M., Klaase, J.M. and IJzerma, M.J. (2013) Individual Risk Profiling for Breast Cancer Recurrence: Towards Tailored Follow-Up Schemes. British Journal of Cancer, 109, 866-871.

[4]   Drukker, C.A., Bueno-de-Mesquita, J.M., Retel, V.P., van Harten, W.H., van Tinteren, H., Wesseling, J., Roumen, R.M., Knauer, M., van’t Veer, L.J., Sonke, G.S., Rutgers, E.J., van de Vijver, M.J. and Linn, S.C. (2013) A Prospective Evaluation of a Breast Cancer Prognosis Signature in the Observational RASTER Study. International Journal of Cancer, 133, 929-936.

[5]   Balkwill, F. and Mantovani, A. (2001) Inflammation and Cancer: Back to Virchow? Lancet, 357, 539-545.

[6]   Bachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A. and Blay, J.Y. (2003) Prognostic Value of Serum Levels of Interleukin 6 and of Serum and Plasma Levels of Vascular Endothelial Growth Factor in Hormone- Refractory Metastatic Breast Cancer Patients. British Journal of Cancer, 88, 1721-1726.

[7]   Pierce, B.L., Ballard-Barbash, R., Bernstein, L., Baumqartner, R.N., Neuhouser, M.L., Wener, M.H., Baumqartner, K.B., Gilliland, F.D., Sorensen, B.E., McTiernan, A. and Urich, C.M. (2009) Elevated Biomarkers of Inflammation Are Associated with Reduced Survival among Breast Cancer Patients. Journal of Clinical Oncology, 27, 3437-3444.

[8]   Lin, M.S., Huang, J.X., Zhu, J. and Shen, H.Z. (2012) Elevation of Platelet Count in Patients with Colorectal Cancer Predicts Tendency to Metastases and Poor Prognosis. Hepatogastroenterology, 59, 1687-1690.

[9]   Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity, 21, 137-148.

[10]   Leitch, E.F., Chakrabarti, M., Crozier, J.E., McKee, R.F., Anderson, J.H., Horgan, P.G. and McMillan, D.C. (2007) Comparison of the Prognostic Value of Selected Markers of the systemic Inflammatory Response in Patients with Colorectal Cancer. British Journal of Cancer, 97, 1266-1270.

[11]   Ege, H., Gertz, M.A., Markovic, S.N., Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Kumar, S.K. and Porrata, L.F. (2008) Prediction of Survival Using Absolute Lymphocyte Count for Newly Diagnosed Patients with Multiple Myeloma: a Retrospective Study. British Journal of Haematology, 141, 792-798.

[12]   Sato, H., Tsubosa, Y. and Kawano, T. (2012) Correlation between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoajuvant Chemotherapy in Patients with Advanced Esophageal Cancer. World Journal of Surgery, 36, 617-622.

[13]   Asher, V., Lee, J., Innamaa, A. and Bali, A. (2011) Preoperative Platelet Lymphocyte Ratio as an Independent Prognostic Marker in Ovarian Cancer. Clinical and Translational Oncology, 13, 499-503.

[14]   Kwon, H.C., Kim, S.H., Oh, S.Y., Lee, S., Lee, J.H., Choi, H.J., Park, K.J., Roh, M.S., Kim, S.G., Kim, H.J. and Lee, J.H. (2012) Clinical Significance of Preoperative Neutrophil-Lymphocyte versus Platelet-Lymhpcyte Ratio in Patients with Operable Colorectal Cancer. Biomarkers, 17, 216-222.

[15]   Azab, B., Shah, N., Radbel, J., Tan, P., Bhatt, V., Vonfrolio, S., Habshy, A., Picon, A. and Bloom, S. (2013) Pretreatment Neutrophil/Lymphocyte Ratio Is Superior to Platelet/Lymphocyte Ratio as a Predictor of Long-Term Mortality in Breast Cancer Patients. Medical Oncology, 30, 432.

[16]   Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thurlimann, B., Senn, H.J. and Panel Members (2011) Strategies for Subtype-Dealing with the Diversity of Breast Cancer: Highlight of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology, 22, 1736-1747.

[17]   Noh, H., Eomm, M. and Han, A. (2013) Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients. Journal of Breast Cancer, 16, 55-59.

[18]   Kanda, Y. (2013) Investigation of the Freely Available Easy-to-Use Software “EZR” for Medical Statistics. Bone Marrow Transplantation, 48, 452-458.

[19]   Bambace, N.M. and Holmes, C.E. (2011) The Platelet Contribution to Cancer Progression. Journal of Thrombosis and Haemostasis, 9, 237-249.

[20]   Suzuki, K., Aiura, K., Ueda, M. and Kitajima, M. (2004) The Influence of Platelets on the Promotion of Invasion by Tumor Cells and Inhibition by Antiplatelet Agents. Pancreas, 29, 132-140.

[21]   Benoy, I., Salgado, R., Colpaert, C., Weytjens, R., Vermeulen, P.B. and Dirix, L.Y. (2002) Serum Interleukin 6, Plasma VEGF, Serum VEGF, and VEGF Platelet Load in Breast Cancer Patients. Clinical Breast Cancer, 2, 311-315.

[22]   Brown, K.M., Domin, C., Aranha, G.V., Yong, S. and Shoup, M. (2005) Increased Preoperative Platelet Count Is Associated with Decreased Survival after Resection for Adenocarcinoma of the Pancreas. The American Journal of Surgery, 189, 278-282.

[23]   Placke, T., Kopp, H.G. and Salih, H.R. (2012) The Wolf in Sheep’s Clothing: Platelet-Derived “Pseudo Self” Impairs Cancer Cell “Missing Self” Recognition by NK Cells. Oncoimmunology, 1, 557-559.

[24]   Ownby, H.E., Roi, L.D., Isenberg, R.R. and Brennan, M.J. (1983) Peripheral Lymphocyte and Eosinophil Counts as Indicator of Prognosis in Primary Breast Cancer. Cancer, 52, 126-130.<126::AID-CNCR2820520123>3.0.CO;2-Y

[25]   Mahmoud, S.M., Paish, E.C., Powe, D.G., Macmillan, R.D., Grainge, M.J., Lee, A.H., Ellis, I.O. and Green, A.R. (2011) Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer. Journal of Clinical Oncology, 29, 1949-1955.